Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2007
Business Overview: Curis is a drug discovery and development company focused on leveraging biological signaling pathway technologies to create targeted medicines, primarily for cancer, neurological, and cardiovascular diseases. The company operates in a single segment: developmental biology products. It has never been profitable and relies on strategic collaborations, license fees, and equity/debt financing to fund operations.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2007) | Value |
|---|---|
| Net Revenues | $3,591,510 |
| Net Loss | $(7,538,317) |
| Net Loss Per Share (Basic & Diluted) | $(0.15) |
| Cash and Cash Equivalents (End of Period) | $15,167,137 |
| Marketable Securities | $15,061,066 |
| Total Current Assets | $30,743,177 |
| Total Current Liabilities | $4,714,227 |
| Debt (Current Portion) | $1,115,634 |
| Debt (Long-Term) | $40,038 |
| Accumulated Deficit | $(696,421,812) |
| Net Cash Used in Operating Activities | $(5,918,131) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 22% to $3.59 million for the six months ended June 30, 2007, compared to $4.60 million in the prior year period. This was driven by a 63% drop in research and development contract revenues due to the conclusion of funding from Genentech (Wnt signaling), Centocor, and the Spinal Muscular Atrophy Foundation.
- License Fee Increase: License fees increased 165% to $1.63 million, primarily due to the accelerated amortization of deferred revenue following the termination of the Procter & Gamble collaboration and the non-extension of the Genentech Wnt collaboration.
- Expense Reduction: Total costs and expenses decreased 12% to $11.65 million. Research and development expenses fell 13% to $6.34 million, and General and Administrative expenses fell 9% to $5.31 million. G&A savings were largely due to reduced occupancy costs following the settlement of a sublease default and the conclusion of a facility lease.
- Impairment Charges: The company recorded a $318,000 impairment charge for property and equipment (discovery screening equipment) and a $145,000 impairment charge for an investment in ES Cell International.
Outlook, Risks, and Management Commentary
- Liquidity: As of June 30, 2007, the company held approximately $30.2 million in cash, cash equivalents, and marketable securities. Management estimates these resources, combined with contractually defined research funding from Wyeth (through February 2008), will sustain operations into the fourth quarter of 2008.
- Collaboration Terminations:
- Procter & Gamble: Terminated the collaboration effective November 9, 2007, regarding Hedgehog agonists for hair growth.
- Ortho Biotech: Received notice of termination for the BMP-7 license agreement, effective August 16, 2007.
- Genentech: The Wnt signaling pathway research term ended March 31, 2007, with no extension. Genentech assumed full responsibility for future development.
- Pipeline Progress: Curis selected CUDC-101, a multi-target small molecule for cancer, as its first development candidate from its internal Targeted Cancer Drug Development Platform. The company anticipates filing an Investigational New Drug (IND) application with the FDA in the first quarter of 2008.
- Risks: The company faces significant risks regarding its ability to raise additional capital, the success of preclinical and clinical trials, and the potential for further collaboration terminations. It also notes a history of financial restatements related to revenue recognition errors in prior years.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $30.2 million cash position to fund operations through Q4 2008, considering the loss of third-party research funding from Genentech and Procter & Gamble.
- Revenue Recognition: Review the accelerated amortization of deferred revenue from terminated collaborations (P&G, Genentech) to understand the non-recurring nature of the license fee revenue spike.
- Debt Covenants: Confirm continued compliance with the minimum working capital ratio covenant required by the Boston Private Bank & Trust Company loans.
- Asset Impairments: Assess the impact of the $318,000 equipment impairment and $145,000 investment write-down on future R&D capabilities and balance sheet strength.
- IND Timeline: Monitor the progress of CUDC-101 preclinical toxicology studies and the projected Q1 2008 IND filing date.